Treatment of pre-cervical cancer lesions Yahong Medicine was approved by APL-1702 PHASE III clinical trial.

In addition to China, Yahong Pharma has launched this internationally registered clinical trial in the United States and Germany, Romania, Hungary, Russia, Ukraine and other European countries, the results of which will be used to support registration applications from China, the United States, the European Union and other countries.
a pl-1702 (Cevira ®) APL-1702 (Cevira ®) is a combination of photodynamic synopsis that combines photosensitive agents with specific wavelengths of photoactivation to produce therapeutic effects based on photodynamics.
goal is to treat patients diagnosed with cervical high-level squamous epithelial lesions (HSIL) in histopathology 18 years of age, including all HPV virus subtypes.
APL-1702 is easily placed on the cervix by a gynaecologist and can be removed by the patient after the end of treatment, which does not affect the patient's daily activities.
, patients are usually treated only once or twice atimeta aforey.
APL-1702, a breakthrough product that will provide patients in China and around the world with a new treatment option that exempts some patients from the pain and side effects of surgical treatment, especially to avoid the impact of surgery on future reproductive function.
APL-1702 (Cevira ®) was also awarded the Fierce Life Sciences Innovation Award 2019 Best Medical Device Innovation Award with an international reputation.
to date, non-surgical products have not been approved globally in the field of precancerous lesions.
.